JNJ : Analysis & Opinions

  • Showing 1-100 of 189 items
  • 1
  • 2
  • >>
  1. Johnson & Johnson Seeks to Deliver 10 Blockbusters

    May 22, 2015
    Healthcare conglomerate Johnson & Johnson (NYSE: JNJ) might be stuck in a bit of a trading range over the past year, ...
  2. Can This J&J Drug Reshape Schizophrenia Treatment?

    May 21, 2015
    Keeping schizophrenia patients on their medication is one of the biggest challenges facing mental health doctors. That means ...
  3. Which Dow Jones Stocks are Safe? Which are Risky?

    May 20, 2015
    In a situation where our sustained bull run could turn into a sell-off rather quickly, here are four somewhat safe Dow stocks ...
  4. Who are Pfizer's (PFE) main competitors?

    May 20, 2015
    Learn about Pfizer's place in the pharmaceutical industry, and find out which major drug manufacturers are among its main ...
  5. Houston, Johnson & Johnson May Have a Problem

    May 19, 2015
    When it comes to potential "safe haven" investments, healthcare conglomerate Johnson & Johnson (NYSE: JNJ) is often ...
  6. 7 Things Johnson & Johnson Wants You to Know

    May 12, 2015
    Last month, healthcare conglomerate Johnson & Johnson (NYSE: JNJ) reported its first-quarter earnings results, essentially ...
  7. Countries Most Affected By A Strong U.S. Dollar

    May 6, 2015
    The U.S. dollar is still the most important currency in the world. It's used for trade, foreign reserves, and as a substitute ...
  8. 3 Top Pharma Stocks that Pay Regular Dividends

    May 1, 2015
    The low down on three big name, dividend-paying pharma stocks.
  9. How to Analyze Pharma Stock Fundamentals

    April 23, 2015
    What you need to know about analyzing the fundamentals of pharma stocks.
  10. Johnson & Johnson's New Billion-Dollar Blockbuster

    April 17, 2015
    Invokana, one of Johnson & Johnson's (NYSE: JNJ) newest drugs, was a bright spot in the company's otherwise lackluster ...
  11. Are J&J's Results a Harbinger of Things to Come?

    April 15, 2015
    Johnson & Johnson (NYSE: JNJ) has reported its first-quarter financial results, and those results, while solid, show ...
  12. Are Sales for This J&J Drug About to Stall?

    April 13, 2015
    Johnson & Johnson (NYSE: JNJ)is a global healthcare giant that racked up $32.3 billion in sales from pharmaceuticals ...
  13. Johnson & Johnson Earnings: 5 Key Things to Watch

    April 10, 2015
    Earnings season is readying to kick off in a big way, and within the health care sector most eyes are beginning to shift ...
  14. Gilead's Little Tweak Could Produce Big Revenue

    April 8, 2015
    Sometimes it's the little things companies do that can have the biggest impacts on their bottom line. Take Gilead Sciences ...
  15. 3 Long-Tail Growth Drivers for Johnson & Johnson

    April 6, 2015
    For the most part, Wall Street and investors love the Big Pharma sector. Large pharmaceutical companies often have diverse ...
  16. Four Key Pharmaceuticals ETFs To Consider

    March 25, 2015
    ETF funds are now very liquid investments and are suitable to investors who seek to match the price performance of the indexes ...
  17. Why These Could Be 2015's 10-Best Pharma Stocks

    March 17, 2015
    The pharmaceutical stocks covered here have significant potential going forward. Here's why.
  18. Traders Look To Dividend Funds (VIG)

    March 6, 2015
    When uncertainty creeps into the mind of an active trader it is not uncommon for this type of person to turn toward the safety ...
  19. How the S&P 500 and Russell 2000 Indexes Differ

    January 22, 2015
    The S&P 500 and Russell 2000 are used as benchmarks for broader segments of the U.S. stock market. Each index has its own ...
  20. Most Powerful And Influential Public Companies In 3 Metrics

    December 9, 2014
    There are many ways to rank the word's most powerful companies. Looking at market value, brand value or sales revenue are ...
  21. The Best Way Into Big Pharma? See This ETF (IHE)

    November 21, 2014
    Pharma investing isn't for everyone, but sector-specific ETFs, such as the iShares Dow Jones U.S. Pharmaceuticals ETF (IHE), ...
  22. 3 Healthcare Stocks To Hedge Against Rising Medical Costs

    October 29, 2014
  23. 3 Healthcare Stocks To Profit From An Aging America

    October 29, 2014
  24. How do you compare the Dow Jones Industrial Average (DJIA) and ...

    October 2, 2014
    See how the Dow Jones Industrial Average and TSX Composite move according to factors in their respective countries and from ...
  25. Who are Amgen Inc.'s (AMGN) main competitors?

    August 27, 2014
    Biotech giant Amgen (AMGN) list of competitors is lengthy and formidable. Learn the major companies Amgen competes with.
  26. Shocking Prediction #9: 'Nightmare Pandemics' Could Make These ...

    August 27, 2014
    Let me start off today's issue with a warning... We're not trying to sound alarmist. It does absolutely zero good ...
  27. Is Now The Time For Momentum Stocks?

    July 11, 2014
    In active trading, strong trends can last longer than traders expect. This has led to a surge of purpose-built exchange traded ...
  28. Interested In Healthcare Stocks? Look At This ETF

    July 3, 2014
    Healthcare companies seem to be poised to make a move higher over the months ahead. Here's an ETF that should be helpful ...
  29. This Company Is No Mickey Mouse Operation

    June 4, 2014
    With its famous history that's become part of popular culture, and the instantly recognizable silhouette in its logo, The ...
  30. How Johnson & Johnson Became A Household Name

    April 21, 2014
    New Brunswick, N.J.-based Johnson & Johnson (NYSE:JNJ) is probably most famous as the parent company of multiple household ...
  31. How Some Brands Come Back from Near Death

    April 17, 2014
    Some company brands manage to revive themselves, while others die and go to brand heaven.
  32. Hedge Funds Love These 3 Pharma Stocks

    April 14, 2014
    In 2012, the star performer among sectors was the financial sector. In 2013, it was consumer discretionary stocks. For 2 ...
  33. How To Smooth-Out Your Ride In The Stock Market

    March 3, 2014
    Volatility is back. For investors, this nasty problem of gyrating markets can be a real hindrance to your portfolio’s total ...
  34. Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, ...

    September 14, 2013
    Declining short interest in Alexion Pharmaceuticals (NASDAQ: PCYC) bucked the trend among leading biotech and emerging pharmaceutical ...
  35. 14 Companies That Have Raised Their Dividends For 50 Years Or ...

    September 10, 2013
    Imagine if you had bought these stocks 20 years ago.If you had, then right now you'd be earning dividend yields of... ...
  36. Akorn Scores A Rare Win-Win Acquisition

    August 27, 2013
    Akorn builds value by buying Hi-Tech
  37. Medtronic Marking Time

    August 20, 2013
    Medtronic looks stuck in low-growth mode for now, but the shares look undervalued.
  38. Danaher Could Be Loading Up For A Bigger 2014

    August 14, 2013
    Danaher has the resources to make some major purchases, but prices and expectations may be a little high.
  39. The Street Has Caught Covidien

    August 1, 2013
    Covidien's quality isn't the issue, but Wall Street's love for it may be.
  40. After A Sharp Pullback, Is Allergan Pretty Enough?

    July 31, 2013
    Down on fears about generics and the pipeline, the Street may be underestimating Allergan
  41. Roche Delivering Leverage, But Still Needs Diversification

    July 29, 2013
    If Roche can balance out its sales mix, the long-term value could be quite compelling at present prices.
  42. Celgene Only Getting Started, But The Street's Already Looking ...

    July 26, 2013
    Biotech valuations are into the nose-bleed zone, but Celgene continues to execute very well.
  43. Stryker Seems Back On Track

    July 19, 2013
    Stryker's revenue growth looks fine, but there are still pressures in the end markets.
  44. Where Do The Bears Go Next With St. Jude Medical?

    July 18, 2013
    St. Jude continues to defy bearish expectations of major share loss, but the shares aren't exactly cheap today.
  45. Abbott Labs Making Progress On Margins, Now It Needs More Growth

    July 17, 2013
    Abbott's results were just so-so, as both margins and growth need more momentum.
  46. Drugs Driving JNJ, With Slow Progress In Devices And Consumer

    July 17, 2013
    JNJ is getting great performance out of its drug business, but the remainder still lags.
  47. Prestige Brands Gets Upgraded: Should You Be Buying?

    July 11, 2013
    At least two investment firms upgraded Prestige Brands' (NYSE:PBH) stock July 9 on news it had acquired a small Australian ...
  48. Intuitive Surgical's Miss Looks Systemic And Company-Specific

    July 9, 2013
    A surprising drop in U.S. system placements is going to put Intuitive Surgical in the penalty box.
  49. Short Interest in Biogen Idec and Vertex Shrinks (BIIB, CELG, ...

    June 26, 2013
    Among biotech and emerging pharmaceutical companies, Celgene (NASDAQ: CELG) and saw the most significant rise in short interest ...
  50. Rising 10-Year Yields Could Crush Popular Dividend ETFs

    June 21, 2013
    Seduced by backward-looking dividend increase streaks, investors have fallen in love with dividend ETFs such as the Vanguard ...
  51. Roche, Reloaded

    May 21, 2013
    Roche has one of the best long-term growth profiles in the Big Pharma space
  52. Little Left To Dendreon But The Hope Trade

    May 10, 2013
    Dendreon looks increasingly irrelevant as the medical community moves on from Provenge.
  53. Recent Financials May Not Be Entirely Fair To Hologic

    May 8, 2013
    Macro pressures are outweighing solid internal progress at Hologic.
  54. In A Growth-Starved Sector, Becton Dickinson Rules

    May 3, 2013
    Becton Dickinson is a great business, but investors seem to be too willing to overpay for today's relatively stronger growth. ...
  55. It Gets A Little Harder From Here For Covidien

    April 29, 2013
    Expectations are the bigger issue for Covidien, as underlying growth is still pretty good on a relative basis.
  56. Kimberly-Clark Looks Way Too Expensive For What It Is

    April 22, 2013
    Kimberly-Clark's growth prospects make today's valuation hard to justify.
  57. Is Controversy About Robot-Assisted Surgery Showing In Intuitive ...

    April 19, 2013
    Uncertainty about procedure growth may be opening a window in these often-expensive shares
  58. Broad Weakness Makes It Harder To Like St. Jude Today

    April 18, 2013
    Although I do believe the long-term expectations for St. Jude are increasingly beatable, this could be a frustrating stock ...
  59. Pharma Is Doing All The Pulling For Johnson & Johnson

    April 17, 2013
    Although JNJ reported decent earnings and has some major new drugs lined up - downside risk is definitely still present.
  60. P&G Rewards Longs With Better Sales And Stronger Margins

    January 30, 2013
    Procter & Gamble is delivering on its promises for better performances.
  61. What Do All-Time-Highs Indicate For These Stocks Going Forward?

    January 30, 2013
    Some well-known names are making all-time highs, and exhibiting very strong uptrends. The question is where to get in?
  62. Shabby Reporting And Questionable Prospects At Abbott Labs

    January 28, 2013
    Poor reporting and weak margins undermine the potential of Abbott.
  63. Stryker Follows Its Rivals With A Big Investment In China

    January 22, 2013
    Stryker's acquisition of Trauson is the right deal at the right time.
  64. Smith & Nephew's Costly Deal

    November 29, 2012
    Smith & Nephew is having to pay a pretty hefty price for this growth injection and this just isn't a sustainable long-term ...
  65. Medtronic's Growth Looks Good, But Can It Last?

    November 22, 2012
    Medtronic may not be a super grower anymore, but it's doing better than the Street seems to acknowledge
  66. Schiff Creates A Bidding War

    November 19, 2012
    Two weeks after Bayer offered to buy Schiff for $34 a share, Reckitt Benckiser is offering $42 a share. A bidding war has ...
  67. Endo Health Solutions Needs Some Solutions Of Its Own

    November 7, 2012
    Can Endo reestablish itself as a quality healthcare name?
  68. Is “Less Bad” As Good As It Gets For Dendreon?

    November 5, 2012
    Dendreon has made progress with its expenses, but the sluggish revenue growth is still the major problem.
  69. GE's Results Reflect An Industrial Slowdown, But Valuation Isn't ...

    October 23, 2012
    GE may have disappointed, but the company and its stock are both in good shape today.
  70. These Companies Have Raised Their Dividends for 50 Consecutive ...

    October 18, 2012
    Imagine if you had bought these stocks 20 years ago. If you had, then right now you'd be earning dividend yields of... 27%... ...
  71. Drugs Have Moved J&J On To A New Phase

    October 17, 2012
    J&J is back on a growth track, but the device business needs fixing.
  72. The Long-Tail Value Of Supreme Brands

    September 25, 2012
    Brand value can make old products into incredible winners.
  73. Valeant Works Its Mojo With Medicis

    September 7, 2012
    Valeant makes a bold but logical bid for Medicis.
  74. Buffett Sold Almost $3 Billion of these 3 Well-Known Stocks

    August 16, 2012
    As one of the world's most successful and prolific investors, it's no wonder Warren Buffett is closely watched by the stock ...
  75. Pfizer Looks To Spin Off Animal Health Unit

    August 15, 2012
    Pfizer has filed plans to sell up to 20% of its animal-health unit in the first half of 2013 to focus on human pharmaceuticals. ...
  76. The Week Ahead In Healthcare

    August 13, 2012
    The performance of healthcare stocks (as measured by ETFs) has begun to falter a bit, likely in part because Johnson & ...
  77. The Week Ahead In Healthcare

    August 8, 2012
    The week ahead for healthcare stocks.
  78. More Healthy Alternatives To Zimmer

    July 30, 2012
    Zimmer has turned to cost cutting to keep total profit growth moving positively forward, but doesn't appear to have any answers ...
  79. 4 Dividend ETFs With Higher Yields Than LQD

    July 24, 2012
    Once upon a time, the conventional wisdom was that investors should hold stocks as a source of long-term capital appreciation ...
  80. Healthcare Stocks Continuing To Outperform

    July 18, 2012
    These healthcare stocks are still on fire, with potentially more upside left. But is that actually bad for the stock market?
  81. Bio-Reference Labs Taking Advantage Of Esoteric Opportunities

    June 22, 2012
    The decision of whether to buy Bio-Reference really comes down to an investor's confidence in the growth prospects for the ...
  82. Rockwood Has Its Risks, But Also Some Apparent Value

    May 31, 2012
    Rockwood has economic risks, but offers real growth opporunities in higher-value lithium and ceramics.
  83. 5 Easy Ways to Cash In on US Dividends

    April 26, 2012
    If you’re outside the US looking in, there are important pros and cons to adding exchange traded funds from America to your ...
  84. Beware These Dividend Red Flags

    April 17, 2012
    Companies paying out more than half their earnings or offering very rich yields might be riskier then investors reckon, says ...
  85. 7 Great Names for Dividend Yield

    March 30, 2012
    Large, dividend-paying equities are good portfolio additions in this low-interest-rate environment, says asset manager Chip ...
  86. Ruling Or Not, Healthcare Still Wins

    March 29, 2012
    The Affordable Care Act finally goes in front of the Supreme Court. However, the Justice’s ruling may not matter. Healthcare ...
  87. Dividends That Will Keep Growing

    March 26, 2012
    The value that these companies have created over the years is mainly due to the dividends they pay out to investors.
  88. 5 Reasons to Love Dividend Growth

    March 15, 2012
    What a smart strategy for DIY investors: It’s idiot and inflation proof, it’s money for nothing…and best of all, it works, ...
  89. Birth Control Subsidies Slashed: Will Big Pharma Take A Hit?

    March 6, 2012
    Several states have already slashed birth control subsidies. Learn how this will affect pharmaceutical stocks.
  90. 5 Dow 30 Stocks With Huge Dividends

    February 27, 2012
    We combed through the Dow 30 to find some of its highest-yielding stocks.
  91. The 10 Must-Know Market Forces for 2012

    February 14, 2012
    For the first time since 2007, investors have multiple ways to succeed this year. Understanding how the lingering effects ...
  92. Procter & Gamble Feels The Pinch

    January 31, 2012
    U.S sales growth combined with rising input costs helped put a lid on the company's quarter.
  93. Colgate-Palmolive Has Growth, But It'll Cost Ya

    January 30, 2012
    Colgate has great growth, but a valuation to match.
  94. Treat Stocks Like Savings

    January 30, 2012
    These sensible stocks are likely to provide consistent returns, and would have beaten many professional picks during the ...
  95. Abbott Labs Dividing Its Growth And Income Potential

    January 26, 2012
    With the coming split of operations, Abbott Labs investors will better be able to choose between growth and income.
  96. Stryker Leaning Away From Knees

    January 26, 2012
    A fair amount of future growth is already baked into Stryker’s valuation.
  97. The Long-Term Play In Lab Work

    January 16, 2012
    As drugmakers beef up their pipelines in this world of rising costs, the contract research sector should profit.
  98. A Better ETF for Metals Investors

    January 11, 2012
    The most common silver and gold ETFs may present risks unknown to most investors, says asset manager and analyst Mo Dawoud. ...
  99. Slow And Steady ETFs Outperforming

    January 3, 2012
    Low volatility ETFs lead the way in 2011.
  100. 2011's Biggest Mergers and Acquisitions

    December 30, 2011
    M&A activity rebounded in a big way in 2011. Here's a look back at the biggest mergers and acquisitions during the year.
  • Showing 1-100 of 189 items
  • 1
  • 2
  • >>
Trading Center